Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 55.45% | $53.29M | 0.5% |
CPRJ | 55.39% | $48.46M | 0.69% |
ARKG | 53.45% | $977.87M | 0.75% |
XBI | 48.17% | $5.33B | 0.35% |
IWC | 43.36% | $810.14M | 0.6% |
IBB | 42.74% | $5.92B | 0.45% |
PBE | 41.99% | $233.11M | 0.58% |
VTWO | 41.43% | $10.91B | 0.07% |
IWM | 41.25% | $64.21B | 0.19% |
XTN | 40.91% | $160.81M | 0.35% |
IWO | 40.88% | $10.88B | 0.24% |
KJAN | 40.61% | $318.03M | 0.79% |
SCHA | 40.23% | $15.95B | 0.04% |
NUSC | 40.08% | $1.11B | 0.31% |
IWN | 39.89% | $10.97B | 0.24% |
ESML | 39.67% | $1.76B | 0.17% |
KAPR | 39.56% | $185.00M | 0.79% |
GSSC | 39.42% | $512.57M | 0.2% |
SLYV | 39.40% | $3.73B | 0.15% |
IJS | 39.35% | $6.40B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DUSB | <0.01% | $1.15B | 0.15% |
MUST | -0.02% | $405.02M | 0.23% |
SOYB | -0.08% | $25.81M | 0.22% |
ULST | 0.11% | $587.03M | 0.2% |
TAXF | 0.21% | $515.52M | 0.29% |
CMDY | 0.28% | $306.57M | 0.28% |
MLN | 0.29% | $531.96M | 0.24% |
GOVZ | -0.32% | $288.61M | 0.1% |
BCI | 0.50% | $1.43B | 0.26% |
AFIF | -0.51% | $135.76M | 1.11% |
XBIL | 0.72% | $708.45M | 0.15% |
TBIL | -0.72% | $5.32B | 0.15% |
XHLF | -0.73% | $1.06B | 0.03% |
IBTP | -0.84% | $108.59M | 0.07% |
DBA | 0.88% | $822.16M | 0.93% |
GCC | 0.89% | $148.21M | 0.55% |
IYK | -0.90% | $1.50B | 0.4% |
IBTF | 0.94% | $2.24B | 0.07% |
SHYD | 0.97% | $319.64M | 0.35% |
BCD | 1.05% | $249.09M | 0.3% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRSP | 59.18% | $2.92B | -50.09% | 0.00% |
FATE | 56.07% | $90.54M | -88.84% | 0.00% |
NTLA | 55.01% | $736.01M | -73.88% | 0.00% |
CRBU | 50.61% | $84.92M | -81.92% | 0.00% |
BEAM | 49.82% | $1.95B | -40.20% | 0.00% |
RXRX | 48.13% | $2.13B | -43.54% | 0.00% |
GT | 46.38% | $2.63B | -31.81% | 0.00% |
ABCL | 46.27% | $664.51M | -49.77% | 0.00% |
RCKT | 43.81% | $711.22M | -75.04% | 0.00% |
AXL | 43.67% | $481.62M | -43.78% | 0.00% |
DNLI | 42.99% | $1.97B | -33.88% | 0.00% |
KAI | 42.48% | $3.97B | +2.93% | 0.38% |
PACB | 40.80% | $351.47M | -67.67% | 0.00% |
PCOR | 40.76% | $9.90B | -17.80% | 0.00% |
ITRN | 40.16% | $758.21M | +29.33% | 4.66% |
ELME | 39.58% | $1.53B | +27.94% | 4.13% |
VRDN | 39.49% | $1.10B | -21.90% | 0.00% |
GPRO | 39.06% | $104.36M | -70.54% | 0.00% |
JBHT | 38.85% | $14.80B | -24.70% | 1.18% |
SDGR | 38.67% | $1.44B | -25.03% | 0.00% |
Double maintains 1 strategies that include ALLO - Allogene Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -31.53% | $404.97M | 1.43% |
VIXY | -20.64% | $195.31M | 0.85% |
TAIL | -15.41% | $86.92M | 0.59% |
UGA | -14.44% | $88.11M | 0.97% |
USDU | -9.59% | $213.46M | 0.5% |
DBE | -9.38% | $54.58M | 0.77% |
BNO | -8.69% | $95.40M | 1% |
DBO | -8.61% | $197.54M | 0.77% |
USO | -7.87% | $1.02B | 0.6% |
COMT | -7.44% | $674.22M | 0.48% |
USL | -7.43% | $46.60M | 0.85% |
OILK | -7.27% | $66.42M | 0.69% |
UUP | -7.19% | $327.80M | 0.77% |
CPER | -7.04% | $205.26M | 0.97% |
IBMO | -6.65% | $505.83M | 0.18% |
VRIG | -5.94% | $1.44B | 0.3% |
GSG | -5.76% | $1.04B | 0.75% |
USCI | -5.43% | $236.09M | 1.07% |
CTA | -5.29% | $963.19M | 0.76% |
FTGC | -5.10% | $2.50B | 1.02% |
Current Value
$1.441 Year Return
Current Value
$1.441 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TW | -0.01% | $31.64B | +43.38% | 0.28% |
HEI.A | -0.02% | $29.31B | +38.35% | 0.10% |
ACGL | 0.02% | $36.14B | +9.57% | 0.00% |
SRRK | 0.03% | $3.04B | +91.48% | 0.00% |
ZTS | 0.05% | $73.73B | -1.42% | 1.09% |
NTNX | -0.09% | $18.62B | +12.02% | 0.00% |
DKL | 0.11% | $2.32B | +6.42% | 10.03% |
SYPR | 0.13% | $37.07M | -2.42% | 0.00% |
CLMT | 0.14% | $1.09B | -14.67% | 0.00% |
FRT | 0.14% | $8.38B | -2.90% | 3.39% |
API | -0.15% | $293.58M | +57.65% | 0.00% |
PGR | -0.16% | $165.90B | +34.80% | 1.73% |
STNG | 0.26% | $1.88B | -48.34% | 4.25% |
FANG | 0.28% | $46.28B | -19.41% | 3.22% |
AU | -0.28% | $18.69B | +67.43% | 2.39% |
ARLP | 0.28% | $3.50B | +35.45% | 10.30% |
LTM | 0.29% | $9.45B | -100.00% | <0.01% |
DY | 0.30% | $4.41B | +9.10% | 0.00% |
EZPW | -0.33% | $808.70M | +32.49% | 0.00% |
CARV | 0.33% | $7.20M | -9.03% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GDDY | -16.12% | $25.46B | +48.74% | 0.00% |
INFA | -13.39% | $5.28B | -50.43% | 0.00% |
CBOE | -13.39% | $23.69B | +24.42% | 1.08% |
CALM | -13.18% | $4.46B | +55.25% | 4.68% |
MSI | -12.59% | $73.09B | +23.82% | 0.95% |
PG | -11.36% | $399.61B | +6.13% | 2.36% |
CHD | -10.79% | $27.09B | +4.83% | 1.03% |
MO | -10.44% | $101.47B | +38.87% | 6.74% |
ENB | -10.38% | $96.56B | +23.67% | 6.00% |
DFIN | -9.96% | $1.25B | -29.61% | 0.00% |
IFRX | -9.93% | $68.48M | -32.89% | 0.00% |
LPTH | -9.42% | $80.72M | +38.62% | 0.00% |
NEXA | -8.50% | $821.12M | -12.68% | 0.00% |
CME | -8.32% | $95.61B | +25.13% | 3.98% |
NOC | -7.80% | $74.12B | +8.63% | 1.60% |
GIS | -7.60% | $32.74B | -14.74% | 3.99% |
WDS | -7.48% | $27.47B | -27.51% | 8.34% |
KNOP | -7.23% | $239.40M | +36.86% | 1.44% |
DVA | -7.19% | $12.24B | +10.98% | 0.00% |
BTCT | -6.73% | $20.20M | +17.54% | 0.00% |
SeekingAlpha
The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.
Yahoo
Allogene Therapeutics ( NASDAQ:ALLO ) Full Year 2024 Results Key Financial Results Net loss: US$257.6m (loss narrowed...
Yahoo
Despite a significant net loss, Allogene Therapeutics Inc (ALLO) advances key trials in large B-cell lymphoma and autoimmune diseases, maintaining a strong cash position.
Yahoo
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
SeekingAlpha
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ETCompany ParticipantsChristine Cassiano - EVP, Chief...
Yahoo
SOUTH SAN FRANCISCO, Calif. AP) — Allogene Therapeutics Inc. ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter.